Journals / Ulusal Travma ve Acil Cerrahi Dergisi / 2010 / Cilt: 16 - Sayı: 4

Levosimendan erken dönem sepsiste aortada "transforming growth factor beta" ve Smad işaretlenmesini up-regüle eder

Levosimendan up-regulates transforming growth factor-beta and Smad signaling in the aorta in the early stage of sepsis

Pages
293–299
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

TGF-β3 immunostaining was mildly increased in groups sham, control and dobutamine, whereas it was found moderate in group levosimendan.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:BACKGROUND This prospective, controlled experimental study was planned to investigate the effects of levosimendan on transforming growth factor (TGF)-β3 and Smad1, Smad2 and Smad3 expression in the early stages of sepsis.
📊
Key Findings & Data:METHODS Twenty-four rats were randomized into four groups: 1) sham-operated controls, 2) dobutamine group - subjected to abdominal hypertension and peritonitis-induced sepsis using cecal ligation and puncture (CLP), then treated with 10 µg.kg-1min-1 intravenous (IV) dobutamine infusion, 3) levosimendan group - as in 2, then treated with levosimendan IV bolus 200 µg.kg-1 followed by 200 µg.kg.-1 min-1 IV infusion, and 4) a control group as in 2, with no treatment.
💡
Conclusion & Impact:TGF-β3 immunostaining was mildly increased in groups sham, control and dobutamine, whereas it was found moderate in group levosimendan.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

BACKGROUND This prospective, controlled experimental study was planned to investigate the effects of levosimendan on transforming growth factor (TGF)-β3 and Smad1, Smad2 and Smad3 expression in the early stages of sepsis. METHODS Twenty-four rats were randomized into four groups: 1) sham-operated controls, 2) dobutamine group - subjected to abdominal hypertension and peritonitis-induced sepsis using cecal ligation and puncture (CLP), then treated with 10 µg.kg-1min-1 intravenous (IV) dobutamine infusion, 3) levosimendan group - as in 2, then treated with levosimendan IV bolus 200 µg.kg-1 followed by 200 µg.kg.-1 min-1 IV infusion, and 4) a control group as in 2, with no treatment. All rats were killed 8 hours after CLP. Aorta tissue samples were analyzed by immunohistochemical staining. RESULTS CLP caused mild interleukin (IL)-1 immunostaining in both control and dobutamine groups. Immunoreactivity of tumor necrosis factor (TNF)-α was mild in both sham and control groups. TGF-β3 immunostaining was mildly increased in groups sham, control and dobutamine, whereas it was found moderate in group levosimendan. Smad1, Smad2 and Smad3 were found moderately increased only in group levosimendan. CONCLUSION Beneficial effects of levosimendan on hemodynamics and global oxygen transport were reported in experimental and clinical trials. Besides its potency on C++ ion sensitivity, it should influence inflammatory cytokine production by diminishing TGF-β3 and Smad1, Smad2 and Smad3 expression.

Özet

AMAÇ Bu prospektif kontrollü deneysel çalışma, levosimendanın erken dönem sepsiste transforming growth factor (TGF)-β3 ve Smad1, Smad2 ve Smad3 oluşumuna etkilerini araştırmak amacıyla planlandı. GEREÇ VE YÖNTEM Yirmi dört sıçan rasgele dört gruba ayrıldı: 1) sham kontrol grubu 2) dobutamin grubu - abdominal hipertansiyon, çekal ligasyon ve delme (ÇLD) tekniği ile peritonit modeli prensibiyle sepsis oluşturuldu, sonra sıçanlar 10 µg.kg-1 dk-1 intravenöz (IV) dobutamin infüzyonu ile tedavi edildi, 3) levosimendan grubu - 2. grupta olduğu gibi sepsis modeli gerçekleştirildi sonra sıçanlar levosimendan IV bolus 200 µg.kg-1 takiben, 200 µg.kg.-1 dk-1 IV infüzyonu ile tedavi edildi, 4) kontrol grubundakilere tedavi yapılmadı. Tüm sıçanlar ÇLD?den 8 saat sonra öldürüldü. Aort doku örnekleri immünohistokimyasal olarak boyandı. BULGULAR ÇLD hem kontrol, hem de dobutamin gruplarında ılımlı IL-1 boyanmasına neden oldu. Tumor necrosis factor (TNF)-α immünreaktivitesi sham ve kontrol grubunda ılımlıydı. Sham, kontrol ve dobutamin gruplarında TGF-β3 ılımlı derecede yüksek bulunurken, bu parametre levosmendan grubunda orta derecede yüksek saptandı. Smad1, Smad2 ve Smad3 levosmendan grubunda orta derecede yükselmiş olarak saptandı. SONUÇ Levosimendanın hemodinami ve global oksijen taşınmasına sağladığı olumlu etkiler, deneysel ve klinik çalışmalarda bildirilmiştir. Levosimendanın C++ iyon duyarlılığı üzerine etkileri yanı sıra, TGF-β3, Smad1, Smad2 ve Smad3 oluşumunu etkileyerek enflamasyonda sitokin salınımına da etkileri olabilir.

🔖

Cite This Article

ERBÜYÜN, K., TOK, D., VATANSEVER, H. S., OK, G., TURKOZ, E., AYDEDE, H., ERHAN, Y., TEKİN, İ. (2010). Levosimendan erken dönem sepsiste aortada "transforming growth factor beta" ve Smad işaretlenmesini up-regüle eder. Ulusal Travma ve Acil Cerrahi Dergisi, Cilt: 16 - Sayı: 4, 293–299. https://ajindex.com/articles/324336

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008;34:17-60
  2. Fiddian-Green RG, Haglund U, Gutierrez G, Shoemaker WC. Goals for the resuscitation of shock. Crit Care Med 1993;21:S25-31
  3. Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994;272:1354-7
  4. Matejovic M, Krouzecky A, Radej J, Novak I. Successful reversal of resistent hypodynamic septic shock with levosimendan.Acta Anaesthesiol Scand 2005;49:127-8
  5. Noto A, Giacomini M, Palandi A, Stabile L, Reali-Forster C, Iapichino G. Levosimendan in septic cardiac failure. Inten- sive Care Med 2005;31:164-5
  6. Powell BP, De Keulenaer BL. Levosimendan in septic shock: a case series. Br J Anaesth 2007;99:447-8
  7. Morelli A, De Castro S, Teboul JL, Singer M, Rocco M, Conti G, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005;31:638-44
  8. Morelli A, Teboul JL, Maggiore SM, Vieillard-Baron A, Rocco M, Conti G, et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med 2006;34:2287-93
  9. Dubin A, Murias G, Sottile JP, Pozo MO, Barán M, Edul VS, et al. Effects of levosimendan and dobutamine in experimental acute endotoxemia: a preliminary controlled study. Intensive Care Med 2007;33:485-94
  10. Cunha-Goncalves D, Perez-de-Sa V, Dahm P, Grins E, Thörne J, Blomquist S. Cardiovascular effects of levosimendan in the early stages of endotoxemia. Shock 2007;28:71-7
  11. Zager RA, Johnson AC, Lund S, Hanson SY, Abrass CK. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol 2006;290:F1453-62
  12. Oda J, Ueyama M, Yamashita K, Inoue T, Harunari N, Ode Y, et al. Effects of escharotomy as abdominal decompression on cardiopulmonary function and visceral perfusion in abdominal compartment syndrome with burn patients. J Trauma 2005;59:369-74
  13. Hobson KG, Young KM, Ciraulo A, Palmieri TL, Greenhalgh DG. Release of abdominal compartment syndrome improves survival in patients with burn injury. J Trauma 2002;53:1129-34
  14. Erbüyün K, Vatansever S, Tok D, Ok G, Türköz E, Aydede H, et al. Effects of levosimendan and dobutamine on experimental acute lung inj